Improved trends in survival and engraftment after single cord blood transplantation for adult acute myeloid leukemia.


Journal

Blood cancer journal
ISSN: 2044-5385
Titre abrégé: Blood Cancer J
Pays: United States
ID NLM: 101568469

Informations de publication

Date de publication:
25 05 2022
Historique:
received: 22 03 2022
accepted: 09 05 2022
revised: 26 04 2022
entrez: 25 5 2022
pubmed: 26 5 2022
medline: 28 5 2022
Statut: epublish

Résumé

Unrelated cord blood transplantation (CBT) is an alternative curative option for adult patients with acute myeloid leukemia (AML) who need allogeneic hematopoietic cell transplantation (HCT) but lack an HLA-matched related or unrelated donor. However, large-scale data are lacking on CBT outcomes for unselected adult AML. To investigate the trends of survival and engraftment after CBT over the past 22 years, we retrospectively evaluated the data of patients with AML in Japan according to the time period of CBT (1998-2007 vs 2008-2013 vs 2014-2019). A total of 5504 patients who received single-unit CBT as first allogeneic HCT for AML were included. Overall survival (OS) at 2 years significantly improved over time. The improved OS among patients in ≥ complete remission (CR)3 and active disease at CBT was mainly due to a reduction of relapse-related mortality, whereas among patients in first or second CR at CBT, this was due mainly to a reduction of non-relapse mortality. The trends of neutrophil engraftment also improved over time. This experience demonstrated that the survival and engraftment rate after CBT for this group has improved over the past 22 years.

Identifiants

pubmed: 35614057
doi: 10.1038/s41408-022-00678-6
pii: 10.1038/s41408-022-00678-6
pmc: PMC9132934
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

81

Informations de copyright

© 2022. The Author(s).

Références

Am J Clin Oncol. 1982 Dec;5(6):649-55
pubmed: 7165009
J Clin Oncol. 2011 Mar 1;29(7):805-13
pubmed: 21220593
Semin Hematol. 1991 Jul;28(3):250-9
pubmed: 1887253
Biol Blood Marrow Transplant. 2017 Jun;23(6):882-896
pubmed: 28279825
J Clin Oncol. 2013 Jul 1;31(19):2437-49
pubmed: 23715573
Bone Marrow Transplant. 2019 Apr;54(4):578-586
pubmed: 30108330
Biol Blood Marrow Transplant. 2009 Mar;15(3):367-9
pubmed: 19203728
Leukemia. 2017 Mar;31(3):663-668
pubmed: 27748373
Biol Blood Marrow Transplant. 2018 Aug;24(8):1671-1677
pubmed: 29684565
Leuk Lymphoma. 2018 Mar;59(3):601-609
pubmed: 28750566
Bone Marrow Transplant. 2020 Apr;55(4):722-728
pubmed: 31591450
Leukemia. 2020 Jan;34(1):128-137
pubmed: 31409921
Transplant Cell Ther. 2021 Apr;27(4):334.e1-334.e11
pubmed: 33836881
Bone Marrow Transplant. 1995 Jun;15(6):825-8
pubmed: 7581076
Leukemia. 2022 Apr;36(4):1132-1138
pubmed: 34815516
Biol Blood Marrow Transplant. 2020 Nov;26(11):2105-2114
pubmed: 32784070
Biol Blood Marrow Transplant. 2015 Jan;21(1):142-50
pubmed: 25445638
Int J Hematol. 2019 Jul;110(1):39-49
pubmed: 31152417
Blood. 2005 Oct 15;106(8):2912-9
pubmed: 15994282
J Intern Med. 2019 Apr;285(4):407-418
pubmed: 30372796
Clin Cancer Res. 2021 Sep 1;27(17):4825-4835
pubmed: 34158357
N Engl J Med. 2016 Jun 9;374(23):2209-2221
pubmed: 27276561
Lancet Haematol. 2019 Nov;6(11):e573-e584
pubmed: 31477550
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Haematologica. 2014 Dec;99(12):e264-8
pubmed: 25216686
Blood. 2013 Jul 25;122(4):491-8
pubmed: 23673863
Bone Marrow Transplant. 1999 Jul;24(2):211-3
pubmed: 10455353
Bone Marrow Transplant. 2019 Nov;54(11):1789-1798
pubmed: 31068659
Int J Hematol. 2016 Jan;103(1):11-9
pubmed: 26588927
Am J Hematol. 2020 Apr;95(4):343-353
pubmed: 31849102
Lancet Oncol. 2010 Jul;11(7):653-60
pubmed: 20558104
Int J Hematol. 2016 Jan;103(1):3-10
pubmed: 26547570
N Engl J Med. 2010 Nov 25;363(22):2091-101
pubmed: 21105791
Biol Blood Marrow Transplant. 2019 Apr;25(4):756-763
pubmed: 30481599
Br J Haematol. 2009 Oct;147(2):262-74
pubmed: 19796275
Ann Intern Med. 2020 Feb 18;172(4):229-239
pubmed: 31958813
Clin Cancer Res. 2017 Nov 1;23(21):6478-6486
pubmed: 28754820
N Engl J Med. 2016 Sep 8;375(10):944-53
pubmed: 27602666
Blood. 2015 Jul 16;126(3):415-22
pubmed: 26031916

Auteurs

Takaaki Konuma (T)

Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. tkonuma@ims.u-tokyo.ac.jp.

Shohei Mizuno (S)

Division of Hematology, Department of Internal Medicine, Aichi Medical University, Nagakute, Japan.

Tadakazu Kondo (T)

Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Yasuyuki Arai (Y)

Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Naoyuki Uchida (N)

Department of Hematology, Toranomon Hospital, Tokyo, Japan.

Satoshi Takahashi (S)

Division of Clinical Precision Research Platform, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Masatsugu Tanaka (M)

Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan.

Takuro Kuriyama (T)

Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan.

Shigesaburo Miyakoshi (S)

Department of Hematology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan.

Makoto Onizuka (M)

Department of Hematology and Oncology, Tokai University School of Medicine, Isehara, Japan.

Shuichi Ota (S)

Department of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan.

Yasuhiro Sugio (Y)

Department of Internal Medicine, Kitakyushu City Hospital Organization, Kitakyushu Municipal Medical Center, Kitakyushu, Japan.

Yasushi Kouzai (Y)

Department of Transfusion Medicine, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan.

Toshiro Kawakita (T)

Department of Hematology, National Hospital Organisation Kumamoto Medical Center, Kumamoto, Japan.

Hikaru Kobayashi (H)

Department of Hematology, Nagano Red Cross Hospital, Nagano, Japan.

Yukiyasu Ozawa (Y)

Department of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan.

Takafumi Kimura (T)

Preparation Department, Japanese Red Cross Kinki Block Blood Center, Osaka, Japan.

Tatsuo Ichinohe (T)

Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.

Yoshiko Atsuta (Y)

Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan.
Department of Registry Science for Transplant and Cellular Therapy, Aichi Medical University School of Medicine, Nagakute, Japan.

Masamitsu Yanada (M)

Department of Hematology and Cell Therapy, Aichi Cancer Center, Nagoya, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH